Fig. 2: Antibody-dependent specificity of DIRECTED.
From: Cell type-specific delivery by modular envelope design
a Titration of αCD3 antibody amount for transduction of Jurkat E6 cells (N = 3 for all conditions). Data was analyzed by an ANOVA followed by a Dunnett’s post-hoc test with a Bonferroni correction. p-values: MOI = 0: 0.525515494, 0.996006008, 0.999997333, 0.999917242, 0.237466884; MOI = 500: 5.38E-09, 0.000421347, 0.024090801, 0.841344411, 0.540949719; MOI = 1000: 1.18E-09, 2.30E-07, 0.012478994, 0.856828212, 0.999999895; MOI = 2000: 3.16E-10, 8.30E-06, 0.038954163, 0.96165626, 0.999993745. b Transduction efficiency (as a percentage of mCherry+ cells) of Jurkat E6 cells (CD3+) and K562 cells (HLA-A2+) in a co-culture with either αCD3-DIRECTED (N = 3 for each condition), αHLA-A2-DIRECTED (N = 3 for each condition), or non-targeting (no antibody, N = 2 for each condition) lentiviral particles. A two-sided Welch’s t-test with Bonferroni correction was used. p-values: aCD3-DIRECTED: 1.95E-05, 8.61E-09, 1.58E-05, 5.52E-05, 4.80E-06, 0.0001883, 6.69E-06; aHLA-A2-DIRECTED: 3.78E-09, 1.32E-06, 2.70E-07, 8.47E-06, 2.81E-07, 2.58E-05, 0.003248; non-targeting: 0.1386, 0.05691, 0.0973, 0.1813, 0.091, 1, 1. [ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; Data are presented as mean ± standard deviation. Source data are provided as a Source Data file].
